Chlorhexidine bathing in a tertiary care neonatal intensive care unit: Impact on central line-associated bloodstream infections

Infection Control and Hospital Epidemiology

Volumn 35, Issue 2, 2014, Pages 158-163

  Quach, Caroline ^a,b   Milstone, Aaron M ^c,d   Perpête, Chantal ^a   Bonenfant, Mario ^b   Moore, Dorothy L ^a,b   Perreault, Therese ^b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE; CHLORHEXIDINE GLUCONATE; TOPICAL ANTIINFECTIVE AGENT;

ANALOGS AND DERIVATIVES; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERIZATION; CROSS INFECTION; HUMAN; HYGIENE; INFANT, NEWBORN, DISEASES; NEWBORN; NEWBORN INTENSIVE CARE; STATISTICS AND NUMERICAL DATA; TERTIARY CARE CENTER;

ANTI-INFECTIVE AGENTS, LOCAL; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CHLORHEXIDINE; CROSS INFECTION; HUMANS; HYGIENE; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INTENSIVE CARE UNITS, NEONATAL; TERTIARY CARE CENTERS;

EID: 84892747011     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/674862     Document Type: Article

References (36)

1. Brodie SB, Sands KE, Gray JE, et al. Occurrence of nosocomial bloodstream infections in six neonatal intensive care units. Pediatr Infect Dis J 2000;19(1):56-65.
2. Schulman J, Stricof R, Stevens TP, et al. Statewide NICU centralline-associated bloodstream infection rates decline after bundles and checklists. Pediatrics 2011;127(3):436-444.
3. Goldmann DA, Freeman J, Durbin WA Jr. Nosocomial infection and death in a neonatal intensive care unit. J Infect Dis 1983; 147(4):635-641.
4. Shah DK, Doyle LW, Anderson PJ, et al. Adverse neurodevelopment in preterm infants with postnatal sepsis or necrotizing enterocolitis is mediated by white matter abnormalities on magnetic resonance imaging at term. J Pediatr 2008;153(2):170-175.e1.
5. Schlapbach LJ, Aebischer M, Adams M, et al. Impact of sepsis on neurodevelopmental outcome in a Swiss National Cohort of extremely premature infants. Pediatrics 2011;128(2):e348-e357.
6. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011;52(9):e162-e193.
7. Chapman AK, Aucott SW, Milstone AM. Safety of chlorhexidine gluconate used for skin antisepsis in the preterm infant. J Perinatol 2012;32(1):4-9.
8. Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008;46(2):274-281.
9. Karki S, Cheng AC. Impact of non-rinse skin cleansing with chlorhexidine gluconate on prevention of healthcare-associated infections and colonization with multi-resistant organisms: a systematic review. J Hosp Infect 2012;82(2):71-84.
10. Exline MC, Ali NA, Zikri N, et al. Beyond the bundle: journey of a tertiary care medical intensive care unit to zero central lineassociated bloodstream infections. Crit Care 2013;17(2):R41.
11. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013;368(6):533-542.
12. Montecalvo MA, McKenna D, Yarrish R, et al. Chlorhexidine bathing to reduce central venous catheter-associated bloodstream infection: impact and sustainability. Am J Med 2012; 125(5):505-511.
13. Rupp ME, Cavalieri RJ, Lyden E, et al. Effect of hospital-wide chlorhexidine patient bathing on healthcare-associated infections. Infect Control Hosp Epidemiol 2012;33(11):1094-1100.
14. Milstone AM, Elward A, Song X, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet 2013;381(9872): 1099-1106.
15. Tamma PD, Aucott SW, Milstone AM. Chlorhexidine use in the neonatal intensive care unit: results from a national survey. Infect Control Hosp Epidemiol 2010;31(8):846-849.
16. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36(5):309-332.
17. Horan TC, Arnold KE, Rebmann CA, Fridkin SK. Network approach for prevention of healthcare-associated infections. Infect Control Hosp Epidemiol 2011;32(11):1143-1144.
18. Horan TC, Emori TG. Definitions of key terms used in the NNIS System. Am J Infect Control 1997;25(2):112-116.
19. Horan TC, Lee TB. Surveillance: into the next millennium. Am J Infect Control 1997;25(2):73-76.
20. National Healthcare Safety Network. Device-Associated Module CLABSI. Atlanta: Centers for Disease Control and Prevention, 2013. http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf. Accessed July 29, 2013.
21. Centers for Disease Control and Prevention (CDC). Device-Associated (DA) Module. Atlanta: CDC, 2009. http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf. Accessed December 16, 2013.
22. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32(8):470-485.
23. Shuman RM, Leech RW, Alvord EC Jr. Neurotoxicity of hexachlorophene in humans. II. A clinicopathological study of 46 premature infants. Arch Neurol 1975;32(5):320-325.
24. Kimbrough RD. Review of recent evidence of toxic effects of hexachlorophene. Pediatrics 1973;51(2):391-394.
25. Tyrala EE, Hillman LS, Hillman RE, Dodson WE. Clinical pharmacology of hexachlorophene in newborn infants. J Pediatr 1977;91(3):481-486.
26. Klieger SB, Potter-Bynoe G, Quach C, Sandora TJ, Coffin SE. Beyond the bundle: a survey of central line-associated bloodstream infection prevention practices used in US and Canadian pediatric hospitals. Infect Control Hosp Epidemiol 2013;34:1208-1210.
27. Cowen J, Ellis SH, McAinsh J. Absorption of chlorhexidine from the intact skin of newborn infants. Arch Dis Child 1979;54(5): 379-383.
28. Garland JS, Alex CP, Uhing MR, Peterside IE, Rentz A, Harris MC. Pilot trial to compare tolerance of chlorhexidine gluconate to povidone-iodine antisepsis for central venous catheter placement in neonates. J Perinatol 2009;29(12):808-813.
29. Chapman AK, Aucott SW, Gilmore MM, Advani S, Clarke W, Milstone AM. Absorption and tolerability of aqueous chlorhexidine gluconate used for skin antisepsis prior to catheter insertion in preterm neonates. J Perinatol 2013;33:768-771.
30. Lee A, Harlan R, Breaud AR, et al. Blood concentrations of chlorhexidine in hospitalized children undergoing daily chlorhexidine bathing. Infect Control Hosp Epidemiol 2011;32(4):395-397.
31. Gongwer LE, Hubben K, Lenkiewicz RS, Hart ER, Cockrell BY. The effects of daily bathing of neonatal rhesus monkeys with an antimicrobial skin cleanser containing chlorhexidine gluconate. Toxicol Appl Pharmacol 1980;52(2):255-261.
32. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis 2006;19(3):290-297.
33. Fritz SA, Hogan PG, Camins BC, et al. Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother 2013;57(1):559-568.
34. Sangal V, Girvan EK, Jadhav S, et al. Impacts of a long-term programme of active surveillance and chlorhexidine baths on the clinical and molecular epidemiology of meticillin-resistant Staphylococcus aureus (MRSA) in an intensive care unit in Scotland. Int J Antimicrob Agents 2012;40(4):323-331.
35. Soma VL, Qin X, Zhou C, Adler A, Berry JE, Zerr DM. The effects of daily chlorhexidine bathing on cutaneous bacterial isolates: a pilot study. Infect Drug Resist 2012;5:75-78.
36. Popovich KJ, Lyles R, Hayes R, et al. Relationship between chlorhexidine gluconate skin concentration and microbial density on the skin of critically ill patients bathed daily with chlorhexidine gluconate. Infect Control Hosp Epidemiol 2012;33(9):889-896.